- Home
- NKX vs VALN Comparison
NKX vs VALN Comparison
Compare NKX & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKX
- VALN
- Stock Information
- Founded
- NKX 2002
- VALN 2012
- Country
- NKX United States
- VALN France
- Employees
- NKX N/A
- VALN N/A
- Industry
- NKX Finance/Investors Services
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NKX Finance
- VALN Health Care
- Exchange
- NKX Nasdaq
- VALN Nasdaq
- Market Cap
- NKX 562.3M
- VALN 542.5M
- IPO Year
- NKX N/A
- VALN 2021
- Fundamental
- Price
- NKX $11.75
- VALN $6.00
- Analyst Decision
- NKX
- VALN Strong Buy
- Analyst Count
- NKX 0
- VALN 3
- Target Price
- NKX N/A
- VALN $15.33
- AVG Volume (30 Days)
- NKX 109.3K
- VALN 14.7K
- Earning Date
- NKX 01-01-0001
- VALN 08-12-2025
- Dividend Yield
- NKX 4.37%
- VALN N/A
- EPS Growth
- NKX N/A
- VALN N/A
- EPS
- NKX N/A
- VALN N/A
- Revenue
- NKX N/A
- VALN $201,099,222.00
- Revenue This Year
- NKX N/A
- VALN $18.74
- Revenue Next Year
- NKX N/A
- VALN $29.26
- P/E Ratio
- NKX N/A
- VALN N/A
- Revenue Growth
- NKX N/A
- VALN 21.64
- 52 Week Low
- NKX $9.78
- VALN $3.62
- 52 Week High
- NKX $12.00
- VALN $8.66
- Technical
- Relative Strength Index (RSI)
- NKX 52.18
- VALN 52.41
- Support Level
- NKX $11.72
- VALN $5.57
- Resistance Level
- NKX $11.81
- VALN $6.19
- Average True Range (ATR)
- NKX 0.08
- VALN 0.29
- MACD
- NKX 0.03
- VALN 0.05
- Stochastic Oscillator
- NKX 81.58
- VALN 65.60
About NKX Nuveen California AMT-Free Quality Municipal Income Fund
Nuveen California AMT-Free Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objectives are to provide current income exempt from regular federal and California income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.